ONGOING
MANAGEMENT RECOMMENDATIONS
| Lab Testing for Adults with Type 2 Diabetes | |
| A1c |
q Twice yearly in patients who are meeting treatment goals q Quarterly in patients whose therapy has changed or who are not meeting treatment goals q Point-of-care testing for A1c allows for timely decisions on therapy changes |
| Fasting lipid panel |
q Fasting lipoprotein panel (total cholesterol, LDL, HDL, triglyceride) obtained after a 9 to 12 hour fast q If fasting lipids not possible/reasonable, consider direct LDL, total cholesterol and HDL q Re-evaluate lipid profiles 6-12 weeks after new therapies are initiated |
| Serum creatinine with
calculated GFR |
q Measure to estimate GFR regardless of the degree of urine albumin excretion q Screen annually. If used for monitoring treatment, more frequent screening is recommended |
| Albumin/Creatinine Ratio |
q Test for protein in urine with albumin to creatinine ratio q Screen annually. If used for monitoring treatment, more frequent screening is recommended |
| Liver enzymes |
q ALT and AST to monitor medication therapy or assess fatty liver |
| Hemoglobin/Hematocrit | q Assess presence of anemia |
| Annual Specialty Referrals | |
| Dilated Eye Exam |
q Retinal exam either through dilated pupils or stereofundus photos. |
| Dental Exam |
q Screen for periodontal disease and examine gums and oral cavity for lesions |